ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -7 مورد

Dimercaptosuccinic acid (succimer): Drug information

Dimercaptosuccinic acid (succimer): Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
Brand Names: US
  • Chemet
Pharmacologic Category
  • Antidote
Dosing: Adult

Note: Consultation with a clinical toxicologist or an expert in the treatment of heavy metal poisoning is highly recommended.

Arsenic poisoning

Arsenic poisoning (off-label use): Dosing is based on the use of succimer for the treatment of lead poisoning (Ref). Consultation with a clinical toxicologist or poison control center is highly recommended in patients who are being considered for chelation therapy.

Oral: 10 mg/kg 3 times daily for 5 days followed by 10 mg/kg twice daily for 14 days (Ref).

Lead poisoning

Lead poisoning (off-label use): Available guidelines recommend chelation therapy with blood lead levels (BLL) >50 mcg/dL and significant symptoms; chelation therapy may also be indicated for most patients with BLL ≥80 mcg/dL and all patients with BLL ≥100 mcg/dL and/or symptoms (Ref). Selection of chelating regimen should be made in consultation with a clinical toxicologist or expert in the treatment of heavy metal poisoning.

Oral: 10 mg/kg 3 times daily for 5 days followed by 10 mg/kg twice daily for 14 days (Ref).

Note: Treatment courses may be repeated, but 2-week intervals between courses is generally recommended because lead re-equilibrates between the extravascular storage sites (eg, bone) and the vascular compartment. High initial blood lead levels (eg, >100 mcg/dL) or presence of lead encephalopathy may indicate the need for more prompt retreatment (Ref); consultation with a clinical toxicologist or poison control center is highly recommended.

Mercury poisoning

Mercury poisoning (off-label use): Dosing is based on the use of succimer for the treatment of lead poisoning (Ref). Consultation with a clinical toxicologist or poison control center is highly recommended in patients who are being considered for chelation therapy.

Oral: 10 mg/kg 3 times daily for 5 days followed by 10 mg/kg twice daily for 14 days (Ref).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Succimer is dialyzable; however, the lead chelates are not.

Dosing: Liver Impairment: Adult

Hepatic impairment prior to treatment: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied. More frequent monitoring of serum transaminases may be required in patients with a history of liver disease due to the risk of transient increases.

Hepatotoxicity during treatment: AST or ALT >5 times ULN: Interrupt therapy or reduce dose.

Dosing: Adjustment for Toxicity: Adult

ANC <1200 mm3: The manufacturer recommends withholding treatment; treatment may be cautiously resumed when ANC returns to baseline or >1500/mm3. May rechallenge if benefits outweigh risk and with more frequent CBC monitoring. Discontinue succimer if signs and symptoms of infection occur.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Dimercaptosuccinic acid (succimer): Pediatric drug information")

Dosage guidance:

Dosing: Dosing is presented in both mg/kg and mg/m2; use caution.

Arsenic poisoning

Arsenic poisoning: Limited data available: Note: Dosing is based on the use of succimer for the treatment of lead poisoning (Ref). Experts recommend dosing for children <5 years of age should be based on body surface area (Ref). Consultation with a clinical toxicologist, poison center, or an expert in the treatment of heavy metal poisoning is highly recommended.

Children <5 years: Oral: 350 mg/m2/dose every 8 hours for 5 days followed by 350 mg/m2/dose every 12 hours for 14 days; maximum dose: 500 mg/dose; round dose to the nearest 100 mg (Ref).

Children ≥5 years and Adolescents: Oral: 10 mg/kg/dose or 350 mg/m2/dose every 8 hours for 5 days followed by 10 mg/kg/dose or 350 mg/m2/dose every 12 hours for 14 days; round dose to the nearest 100 mg; maximum dose: 500 mg/dose (Ref).

Lead poisoning, mild and asymptomatic

Lead poisoning, mild and asymptomatic:

Note: For the treatment of high blood lead levels (BLL) in children, the CDC recommends chelation treatment when BLL >45 mcg/dL (Ref). The AAP recommends succimer as the drug used for initial management in asymptomatic children when BLL >45 mcg/dL and <70 mcg/dL; children with BLL ≥70 mcg/dL or symptomatic lead poisoning should be treated with parenteral agents (Ref). Selection of chelating regimen should be made in consultation with a clinical toxicologist or expert in the treatment of heavy metal poisoning. Assess baseline blood lead concentration, CBC (ensure neutrophils >1,500/mm3), liver transaminases (AST, ALT), and kidney function (BUN, SCr, urine protein).

Children and Adolescents:

Weight or BSA-directed dosing: Oral: Initial: 10 mg/kg/dose or 350 mg/m2/dose every 8 hours for 5 days followed by 10 mg/kg/dose or 350 mg/m2/dose every 12 hours for 14 days; round doses to the nearest 100 mg; maximum dose: 500 mg/dose; maximum daily dose: 1,500 mg/day. Note: Some experts recommend dosing for children <5 years of age should be based on body surface area (Ref).

Weight-band dosing: Oral: Dosing based on weight-directed dosing (10 mg/kg/dose) rounded to nearest 100 mg.

Succimer Weight-Band Dosing in Children and Adolescents for Lead Poisoning

Weight-band

Dose

Frequency

8 to <16 kg

100 mg

Administer dose every 8 hours for 5 days followed by the same dose every 12 hours for 14 days

16 to <24 kg

200 mg

24 to <35 kg

300 mg

35 to <45 kg

400 mg

≥45 kg

500 mg

Repeat courses: Assess BLL at completion (Day 19) of succimer treatment course and weekly until stable. Treatment courses may be repeated with similar BLL monitoring; however, a minimum interval of 2 weeks between courses is generally recommended to identify lead redistribution from extravascular storage sites (eg, bone) to the vascular compartment.

Mercury poisoning

Mercury poisoning: Limited data available: Note: Dosing is based on the use of succimer for the treatment of lead poisoning (Ref). Experts recommend dosing for children <5 years of age should be based on body surface area (Ref); round doses to the nearest 100 mg. Consultation with a clinical toxicologist, poison center, or an expert in the treatment of heavy metal poisoning is highly recommended.

Children <5 years: Oral: 350 mg/m2/dose every 8 hours for 5 days followed by 350 mg/m2/dose every 12 hours for 14 days; maximum dose: 500 mg/dose; round dose to the nearest 100 mg (Ref).

Children ≥5 years and Adolescents: Oral: 10 mg/kg/dose or 350 mg/m2/dose every 8 hours for 5 days followed by 10 mg/kg/dose or 350 mg/m2/dose every 12 hours for 14 days; maximum dose: 500 mg/dose.

Dosing adjustment for toxicity: Children and Adolescents: ANC <1,200/mm3: The manufacturer recommends withholding treatment; treatment may be cautiously resumed at previous dose when ANC returns to baseline or >1,500/mm3. Consult a clinical toxicologist to determine the risk versus benefit of withholding treatment or rechallenge in patients who develop neutropenia.

Dosing: Kidney Impairment: Pediatric

Children and Adolescents: There are no dosage adjustments in the manufacturer's labeling; use with caution and monitor closely; patients with a history of kidney impairment may require more frequent monitoring. Succimer is dialyzable; however, the lead chelates are not.

Dosing: Liver Impairment: Pediatric

Children and Adolescents: Suspend or reduce succimer dosing if ALT or AST >5 × ULN. More frequent monitoring of serum transaminases may be required in patients with a history of liver disease due to the risk of transient increases.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in pediatric patients.

>10%: Gastrointestinal: Gastrointestinal signs and symptoms (12%; including decreased appetite, diarrhea, hemorrhoids, metallic taste, nausea, vomiting)

1% to 10%:

Dermatologic: Papular rash (≤3%), pruritus (≤3%), skin rash (4%), vesicular eruption (mucocutaneous; including oral, perianal, urethral) (≤3%)

Endocrine & metabolic: Hypercholesterolemia (≤4%)

Gastrointestinal: Abdominal cramps (≤5%), stomach pain (≤5%)

Hematologic & oncologic: Eosinophilia (≤1%), neutropenia (≤1%), thrombocytosis (≤1%)

Hepatic: Increased serum alanine aminotransferase (6% to 10%), increased serum alkaline phosphatase (≤4%), increased serum aspartate aminotransferase (6% to 10%)

Infection: Candidiasis (≤5%), herpetic lesion (≤3%)

Nervous system: Chills (≤5%), fatigue (≤5%), headache (≤5%), heavy headedness (≤5%), neurological signs and symptoms (1%; including dizziness, drowsiness, paresthesia, sensorimotor neuropathy)

Neuromuscular & skeletal: Back pain (≤5%), rib pain (≤5%)

Ophthalmic: Cloudy vision (cloudy film in eye) (≤1%), watery eyes (≤1%)

Renal: Flank pain (≤5%)

Respiratory: Flu-like symptoms (≤5%), pulmonary signs and symptoms (4%; including cough, nasal congestion, pharyngitis, rhinorrhea)

Miscellaneous: Fever (≤5%)

Postmarketing: Hypersensitivity: Hypersensitivity reaction (including angioedema)

Contraindications

History of hypersensitivity (eg, angioedema, mucocutaneous vesicular eruptions, urticaria) to succimer or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Hematologic effects: Succimer may cause neutropenia.

• Hepatic effects: Elevations in serum transaminases (ALT/AST) have been reported.

• Hypersensitivity reactions: Hypersensitivity, including angioedema and urticaria, and dermatologic reactions, including mucocutaneous vesicular eruptions, have been reported. Reactions have been reported with repeat administration and may increase with each treatment course. Interrupt therapy if rash or mucocutaneous vesicular eruptions occur; consider rechallenge if lead levels are elevated enough to require treatment.

Disease-related concerns:

• Encephalopathy: Succimer does not cross blood-brain barrier and should not be used to treat encephalopathy associated with lead toxicity.

• Lead poisoning: Investigate, identify, and remove sources of lead exposure prior to treatment; do not permit patients to reenter the contaminated environment until lead abatement has been completed. Consultation with a clinical toxicologist or an expert in the treatment of heavy metal poisoning is highly recommended before initiating chelation therapy. Succimer is not used to prevent lead poisoning. A rebound rise in serum lead levels may occur after treatment as lead is released from storage sites into blood. The severity of rebound may guide the frequency of future monitoring and the need for additional chelation therapy. In a small prospective, randomized, open-label trial, succimer was shown to improve clinical signs and symptoms of lead poisoning and to reduce blood lead levels more effectively than edetate calcium disodium (Sakthithasan 2018).

• Liver impairment: Use with caution in patients with liver impairment.

• Renal impairment: Use with caution in patients with renal impairment. Succimer is dialyzable; however, the lead chelates are not.

Other warnings/precautions:

• Hydration: Adequate hydration should be maintained during therapy.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Chemet: 100 mg

Generic Equivalent Available: US

No

Pricing: US

Capsules (Chemet Oral)

100 mg (per each): $26.44

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Oral: If unable to swallow whole, capsule may be separated and contents sprinkled on a small amount of soft food, or the contents placed on a spoon and administered followed by fruit drink.

Administration: Pediatric

Oral : Capsules: Swallow capsule whole. Ensure adequate patient hydration.

Oral administration on soft food: For patients who cannot swallow the capsule whole, may open the capsule(s) and sprinkle the medicated beads into a small amount of juice or on a small amount of apple sauce, ice cream, or soft food or placed on a spoon and followed with fruit drink to mask the odor. Prepare immediately prior to dose.

Use: Labeled Indications

Lead poisoning: Treatment of lead poisoning in pediatric patients ≥1 year of age with blood lead levels >45 mcg/dL.

Use: Off-Label: Adult

Lead poisoning; Mercury poisoning; Arsenic poisoning

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Reproductive Considerations

Pregnancy testing is recommended prior to succimer use in patients who may become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 14 days after the last dose of succimer.

Consider chelation therapy in patients of child-bearing potential with blood lead levels 45 to 70 mcg/dL, with or without clinical symptoms, to reduce the risk of in utero lead exposure in future pregnancies (WHO 2021).

Pregnancy Considerations

Adverse events were observed in animal reproduction studies.

Lead poisoning: Data related to the use of succimer during pregnancy are limited (CDC 2010; Shannon 2003; WHO 2021). Lead crosses the placenta in amounts related to maternal plasma levels. Prenatal lead exposure may be associated with adverse events such as spontaneous abortion, preterm delivery, decreased birth weight, and impaired neurodevelopment. Some adverse outcomes may occur with maternal blood lead levels <10 mcg/dL. In addition, pregnant patients exposed to lead may have an increased risk of gestational hypertension. Consider chelation therapy in pregnant patients with confirmed blood lead levels ≥45 mcg/dL (pregnant patients with blood lead levels ≥70 mcg/dL should be considered for chelation regardless of trimester); consultation with experts in lead poisoning and high-risk pregnancy is recommended. Encephalopathic pregnant patients should be chelated regardless of trimester (CDC 2010; WHO 2021). An agent other than succimer may be preferred when a chelating agent is needed during the first trimester (WHO 2021).

Breastfeeding Considerations

It is not known if succimer is present in breast milk.

When treating lead poisoning, the amount of lead in breast milk may range from 0.6% to 3% of the maternal serum concentration. Lactating patients with confirmed blood lead levels ≥40 mcg/dL should pump and discard breast milk until blood lead levels are <40 mcg/dL. Monitor infant blood lead levels; if rising or not falling, temporarily discontinue breastfeeding if maternal breast milk is found to be the source (CDC 2010). Calcium supplementation may reduce the amount of lead in breast milk.

Monitoring Parameters

Blood lead levels (baseline and 7 to 21 days after completing chelation therapy); kidney function (baseline and periodically during prolonged treatment); serum transaminases (baseline and weekly during treatment; may require more frequent monitoring in patients with a history of liver disease); CBC with differential and platelets (baseline, and weekly during treatment); hemoglobin or hematocrit, iron status, free erythrocyte protoporphyrin or zinc protoporphyrin; neurodevelopmental changes; mucocutaneous eruptions, including oral, perianal, urethral, especially with repeated doses; signs/symptoms of infection. Pregnancy testing prior to use in patients who may become pregnant.

Mechanism of Action

Succimer is an analog of dimercaprol. It forms water soluble chelates with heavy metals which are subsequently excreted renally. Succimer binds heavy metals; however, the chemical form of these chelates is not known.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Rapid but incomplete

Distribution: Primarily extracellular (Aposhian 1992)

Protein binding: >95% primarily to albumin (Aposhian 1992)

Metabolism: Rapidly and extensively to mixed succimer cysteine disulfides

Half-life elimination: ~3 hours (Aposhian 1992)

Time to peak, serum: ~1 to 2 hours

Excretion: Urine (~25%) with peak urinary excretion between 2 to 4 hours (90% as mixed succimer-cysteine disulfide conjugates, 10% as unchanged drug); feces (as unabsorbed drug)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Molecular weight: 182.2.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (CH) Switzerland: Succicaptal;
  • (CO) Colombia: Chemet;
  • (CZ) Czech Republic: Succicaptal;
  • (FR) France: Succicaptal;
  • (GR) Greece: Succicaptal;
  • (NO) Norway: Succicaptal;
  • (PL) Poland: Succicaptal;
  • (PR) Puerto Rico: Chemet;
  • (PT) Portugal: Chemet;
  • (QA) Qatar: Chemet
  1. Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP). Low-level lead exposure harms children: A renewed call for primary intervention. January 4, 2012. Available at http://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf . Last accessed on March 17, 2017)
  2. Agency for Toxic Substances & Disease Registry (ATSDR). Medical management guidelines for arsenic (As) and inorganic arsenic compounds. 2014a. Available at: https://www.atsdr.cdc.gov/MHMI/mmg2.pdf
  3. Agency for Toxic Substances & Disease Registry (ATSDR). Medical management guidelines for mercury (Hg). 2014b. Available at: https://www.atsdr.cdc.gov/MHMI/mmg46.pdf
  4. American Academy of Pediatrics Committee on Environmental Health. Lead exposure in children: prevention, detection, and management. Pediatrics. 2005;116(4):1036-1046. doi:10.1542/peds.2005-1947 [PubMed 16199720]
  5. Andersen O. Principles and recent developments in chelation treatment of metal intoxication. Chem Rev. 1999;99(9):2683-2710. [PubMed 11749497]
  6. Aposhian HV, Maiorino RM, Rivera M, et al, “Human Studies With the Chelating Agents, DMPS and DMSA,” Clin Toxicol, 1992, 30(4):505-28. [PubMed 1331491]
  7. Bradberry S and Vale A, "Dimercaptosuccinic Acid (Succimer; DMSA) in Inorganic Lead Poisoning," Clin Toxicol (Phila), 2009, 47(7):617-31. [PubMed 19663612]
  8. Centers for Disease Control and Prevention (CDC), Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women, Atlanta: CDC; 2010.
  9. Centers for Disease Control and Prevention (CDC), Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention, Atlanta: CDC; 2002.
  10. Chemet (succimer) [prescribing information]. Bridgewater, NJ: Recordati Rare Diseases Inc; September 2024.
  11. Crinnion WJ, "EDTA Redistribution of Lead and Cadmium into Soft Tissues in a Human With a High Lead Burden: Should DMSA Always be used to Follow EDTA in Such Cases?" Alt Med Rev, 2011, 16(2):109-112. [PubMed 21649453]
  12. Council of State and Territorial Epidemiologists (CSTE). Management guidelines for blood lead levels in adults. https://dhhs.ne.gov/Lead%20Documents/Adult-Lead-Management-Guidelines.pdf. Published June 12, 2013. Accessed February 14, 2022.
  13. Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021 [PubMed 28669553]
  14. Dart RC, Hurlburt KM, Maiorino RM, et al, “Pharmacokinetics of Meso-2,3-Dimercaptosuccinic Acid in Patients With Lead Poisoning and in Healthy Adults,” J Pediatr, 1994, 125(2):309-16. [PubMed 8040783]
  15. Drasch G, Boese-O'Reilly S, Illig S. Increase of renal excretion of organo-mercury compounds like methylmercury by DMPS (2,3-dimercapto-1-propanesulfonic acid, dimaval). Clin Toxicol (Phila). 2007;45(3):266-269. [PubMed 17453878]
  16. Gardella C, “Lead Exposure in Pregnancy: A Review of the Literature and Argument for Routine Prenatal Screening,” Obstet Gynecol Surv, 2001, 56(4):231-8. [PubMed 11285436]
  17. Gracia RC and Snodgrass WR, “Lead Toxicity and Chelation Therapy,” Am J Health Syst Pharm, 2007, 64(1):45-53. [PubMed 17189579]
  18. Howland MA. Antidotes in depth: succimer (2,3-dimercaptosuccinic acid) and DMPS (2,3-dimercapto-1-propanesulfonic acid). In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. Goldfrank's Toxicologic Emergencies. 11th ed. McGraw-Hill; 2018.
  19. Kosnett MJ. The role of chelation in the treatment of arsenic and mercury poisoning. J Med Toxicol. 2013;9(4):347-354. doi:10.1007/s13181-013-0344-5 [PubMed 24178900]
  20. Kosnett MJ, Wedeen RP, Rothenberg SJ, et al. Recommendations for medical management of adult lead exposure. Environ Health Perspect. 2007;115(3):463-471. doi:10.1289/ehp.9784 [PubMed 17431500]
  21. Mann KV and Travers JD, “Succimer, An Oral Lead Chelator,” Clin Pharm, 1991, 10(12):914-22. [PubMed 1663439]
  22. Sakthithasan K, Lévy P, Poupon J, Garnier R. A comparative study of edetate calcium disodium and dimercaptosuccinic acid in the treatment of lead poisoning in adults. Clin Toxicol (Phila). 2018;56(11):1143-1149. doi:10.1080/15563650.2018.1478424 [PubMed 29889577]
  23. Shannon M. Severe lead poisoning in pregnancy. Ambul Pediatr. 2003;3(1):37-39. doi:10.1367/1539-4409(2003)003<0037:slpip>2.0.co;2 [PubMed 1254025]
  24. Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. Pediatrics. 2020;145(1):e20193450. [PubMed 31871244]
  25. World Health Organization (WHO). WHO guideline for clinical management of exposure to lead. https://www.who.int/publications/i/item/9789240037045. Published October 27, 2021. Accessed October 11, 2024. [PubMed 34787987]
Topic 9102 Version 149.0